Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug 27;28(5):e573-e576.
doi: 10.1097/MJT.0000000000001442.

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American Journal of Therapeutics, 28, e434-e460, July 2021

Andrew Bryant  1 , Theresa A Lawrie  2 , Edmund J Fordham  2
Affiliations
Comment

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American Journal of Therapeutics, 28, e434-e460, July 2021

Andrew Bryant et al. Am J Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare. With regard to the authorship of the original article (and the present Letter), all authors except Dr. Dowswell attended the BiRD (British Ivermectin Recommendation Development) meeting comprised of medical doctors, healthcare professionals and other stakeholders, with international representation, which was convened for an “Evidence to Decision” framework event on 20 February 2021. A. Bryant and T. A. Lawrie were members of the Steering Group and did not vote on the decisions. E. J. Fordham, Hill, Mitchell and Tham were ordinary members of the panel. The panel voted to recommend the deployment of ivermectin for the treatment and prevention of Covid-19, upon an evidence base comprising an earlier version of the meta-analysis as published in Am. J. Therap., plus additional supporting evidence. BiRD remains an unincorporated, not-for-profit, ad hoc association with no financial or material interests in ivermectin or any other medicine or any other product. Its continuing activities are transparently managed through EbMCsquared, a not-for-profit Community Interest Company.

Figures

FIGURE 1.
FIGURE 1.
Mortality outcome analysis as in Figure 3 of the study by Bryant et al but with the study by Elgazzar removed.
FIGURE 2.
FIGURE 2.
Prophylaxis outcome analysis as in Figure 15 of the study by Bryant et al but with the study by Elgazzar removed.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Bryant A, Lawrie TA, Dowswell T, et al. . Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther. 2021;28:e434–e460. - PMC - PubMed
    1. Davey M. Huge Study Supporting Ivermectin as Covid Treatment Withdrawn over Ethical Concerns. The Guardian; 2021. Available at: https://www.theguardian.com/science/2021/jul/16/huge-study-supporting-Iv.... Accessed July 22, 2021.
    1. Elgazzar A, Hany B, Youssef SA, et al. . Efficacy and safety of Ivermectin for treatment and prophylaxis of COVID-19 pandemic. Res Square. 2020. doi: 10.21203/rs.3.rs-100956/v2. Available at: https://www.researchsquare.com/article/rs-100956/v2 . Accessed August 9, 2021. - DOI
    1. Elgazzar A. Private Communication. 2021.
    1. Page MJ, McKenzie JE, Bossuyt PM, et al. . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372. doi: 10.1136/bmj.n71. Available at: https://www.bmj.com/content/372/bmj.n71. Accessed August 9, 2021. - DOI - PMC - PubMed